United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - boceprevir (unii: 89bt58kelh) (boceprevir - unii:89bt58kelh) - boceprevir 200 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - boceprevir 200mg - capsule - 200 mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 - victrelis (boceprevir) is indicated for the treatment of chronic hepatitis c (hcv) genotype 1 infection, in a combination regimen with peginterferon alpha and ribavirin, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.

European Union - English - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevir - hepatitis c, chronic - antivirals for systemic use - victrelis is indicated for the treatment of chronic hepatitis-c (chc) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

Canada - English - Health Canada

merck canada inc - boceprevir - capsule - 200mg - boceprevir 200mg - hcv antivirals

Canada - English - Health Canada

merck canada inc - boceprevir; ribavirin; peginterferon alfa-2b - capsule - 200mg; 200mg; 80mcg - boceprevir 200mg; ribavirin 200mg; peginterferon alfa-2b 80mcg - interferons

Canada - English - Health Canada

merck canada inc - boceprevir; ribavirin; peginterferon alfa-2b - capsule - 200mg; 200mg; 100mcg - boceprevir 200mg; ribavirin 200mg; peginterferon alfa-2b 100mcg - interferons

Canada - English - Health Canada

merck canada inc - boceprevir; ribavirin; peginterferon alfa-2b - capsule - 200mg; 200mg; 120mcg - boceprevir 200mg; ribavirin 200mg; peginterferon alfa-2b 120mcg - interferons

Canada - English - Health Canada

merck canada inc - boceprevir; ribavirin; peginterferon alfa-2b - capsule - 200mg; 200mg; 150mcg - boceprevir 200mg; ribavirin 200mg; peginterferon alfa-2b 150mcg - interferons

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - boceprevir -

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - boceprevir 200mg; peginterferon alfa-2b 100ug; ribavirin 200mg;   - combination - 200mg/100mcg/200mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 active: peginterferon alfa-2b 100ug excipient: dibasic sodium phosphate dibasic sodium phosphate monohydrate polysorbate 80 sucrose active: ribavirin 200mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide water for injection - victrelis pegatron combination therapy is indicated for the treatment of chronic hepatitis c (chc) genotype 1 infection, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.